Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowing reproducible and iterative development and application of organoids.
Organoids are three-dimensional cellular models that recapitulate key aspects of organ function. They are used in safety and toxicology screening, drug discovery, disease modeling, and personalized medicine and could replace many instances where animal testing is required. However, organoid use has been hindered by lengthy and highly variable processes to make iPSC aggregates. The PluriForm Organoid Kit solves this challenge by providing a ready-to-use system that includes cryopreserved, Ready-to-Differentiate® (RTD®), suspension-adapted iPSCs and optimized media with a simple protocol. Each kit contains a vial of 25 million cells and all necessary reagents. Within minutes, the end-user can combine the components and generate thousands of uniform aggregates in just one day. These pluripotent aggregates display consistent morphology and size distribution, critical parameters for reproducible differentiation to a wide range of organoids, including neuronal, liver, intestinal, pancreatic, kidney, and cardiac models.
"Our goal is to accelerate the pace of discovery in the pharmaceutical and biotech industries," said Dr. Benjamin Fryer, Co-founder and CEO of Pluristyx. "With PluriForm, we have addressed consistent feedback that the initial step of creating reproducible cell aggregates is a major source of delay and inconsistency in organoid workflows.'
The FDA's Roadmap to Reduced Animal Testing in Preclinical Safety Studies, released in April 2025, explicitly advocates use of organoids to replace animal models. The PluriForm™ Organoid Kit is essential to enabling and accelerating the transition away from use of animals and other less-than-optimal cell assays and is now available for purchase through Pluristyx direct sales channels.
About Pluristyx
Pluristyx enables the development of next-generation therapies and technologies through a portfolio of cutting-edge products and services for the regenerative medicine industry. With a focus on quality, consistency, and scalability, Pluristyx empowers scientists to bring their most innovative concepts from the lab to the clinic. Pluristyx: Tomorrow's Cell Therapies, Today®.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA
KalVista (KALV) Pharmaceuticals nnounced that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application for sebetralstat, the company's investigational oral on-demand treatment for hereditary angioedema. The FDA notified the company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks. The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the company believes the only remaining item under FDA review is the finalization of the labelling. 'We are disappointed by this delay, most importantly because we know how much people living with HAE are looking forward to an oral on-demand option to treat their HAE attacks,' said Ben Palleiko, CEO of KalVista. 'At the same time, we remain confident in the near-term approval of sebetralstat. We are continuing to work closely with the FDA to support the completion of their review. Our commitment to bringing this important therapy to people living with HAE remains unwavering.'
Associated Press
an hour ago
- Associated Press
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. If you purchased or otherwise acquired Rocket shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648
Business Wire
3 hours ago
- Business Wire
Securonix Acquires ThreatQuotient to Deliver Industry's Broadest and Deepest Threat Detection Investigation and Response
PLANO, Texas--(BUSINESS WIRE)--Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of ThreatQuotient, a four-time leader in threat intelligence based on QKS Group Spark Matrix report and the force behind ThreatQ, the most innovative external threat intelligence platform. This combination will create a comprehensive, modular, and fully integrated AI-driven platform for threat detection, investigation, and response (TDIR), leveraging advanced analytics and insights across both internal and external threats. This acquisition accelerates the modernization of security operations by uniting internal and external threat intelligence with real-time analytics and agentic AI. Unlike external threat intelligence bolt-on solutions with disconnected management interfaces, the integrated platform from Securonix and ThreatQuotient will deliver unified visibility, faster response, and greater operational clarity. "Bringing threat intelligence management and SIEM together in a unified platform is a game changer. We've already seen the value of deeply enriched advanced analytics and detection in our Securonix SIEM environment—but coupling that with integrated threat curation, prioritization, and response should help customers move even faster. It means fewer swivel-chair investigations, more accurate triage, and greater confidence that security analysts are working with the most relevant threats. This kind of integration has the potential to accelerate the ability to detect, respond, and stay ahead," said Marcel Jonker, Director of Cybersecurity Operations at Cambia Health Systems. The integration of Securonix and ThreatQuotient promises to deliver up to a 70% reduction in Mean Time to Respond (MTTR), enabling security teams to detect, investigate, and remediate threats significantly faster. By combining curated threat intelligence with AI-driven automation, the solution will deliver exponential improvements in filtering out false positives, enriching alerts with actionable context, and automating historical threat sweeps and incident response. This reduces alert overload, speeds up root cause analysis, and minimizes manual handoffs—cutting investigation time from hours to minutes and enabling automated containment before threats escalate. 'Security teams are drowning in noise and struggling to keep up with evolving threats,' said Kash Shaikh, CEO and President of Securonix. 'This acquisition brings together Securonix's Agentic AI-driven Platform with ThreatQuotient's deep threat intelligence to deliver clarity, speed, and automated workflows to our customers, reducing false positives by up to 90%. Together, we're building the modern SOC Platform—proactive, intelligent, and built for what's next.' Kash added, 'Securonix and ThreatQuotient bring together complementary strengths—deep innovation across internal and external threat domains, and a shared commitment to innovation and customer service. Both companies serve enterprise and government customers as well as managed security service providers (MSSPs), and we're excited to welcome the talented ThreatQuotient team and their customers to Securonix.' Purpose-Built for Analysts. Proven Against Real-World Threats. ThreatQuotient's Threat Intelligence Platform (TIP) strength lies in delivering curated, contextualized threat intelligence that drives smart, timely decisions. When combined with Securonix's EON Agentic AI-based SIEM, SOAR, UEBA and Data Pipeline Manager, customers can accelerate their migration from reactive threat hunting-based defense to proactive, real-time, behavior-driven, open-agentic security operations. With this integration, Securonix customers and partners will enjoy the following benefits: Gain clear visibility: Integrate deep enriched real-time analytics from Securonix with curated external intelligence from ThreatQuotient to create a single, high-context stream of alerts. Eliminate blind spots and accelerate threat identification with confidence. Stay ahead of risk: Auto-enrich Indicator of compromise (IoCs) and preemptively respond to repeat attacks, blocking 90 percent before they start. Act smarter: Automate repetitive tasks, reduce false positives, and streamline investigations. Teams can stay focused on high-priority threats and reduce time spent on manual triage. Deploy your way: Continue to use ThreatQ as a standalone threat intelligence platform or as part of the fully integrated Securonix solution. Deploy on-premise or SaaS in a way that fits the current architecture and scales with needs. Accelerated Roadmap: Combined R&D synergies will accelerate upcoming roadmap innovations, including Agentic AI and ThreatQuotient's innovation priorities. With this acquisition, ThreatQuotient customers and partners will enjoy the following benefits: Increased Scale: ThreatQ customers can take advantage of Securonix's global R&D scale and GTM reach, including access to Securonix's Threat Labs Intelligence. Deeper Integrations: Gain access to an enriched roadmap and integration between Securonix's best-in-class SIEM, SOAR, and UEBA portfolio and ThreatQ, including extension of Agentic AI advancements. Continued Focus: Zero interruption of their existing service, as ThreatQuotient will continue to operate as a standalone offering, with no disruption to existing roadmap and workflows. 'Enterprises, government institutions and managed security service providers rely on ThreatQuotient to protect their mission critical businesses. Joining Securonix marks a powerful new chapter for ThreatQuotient. By uniting our strengths, we can accelerate innovation, expand our reach, and deliver greater value to our customers. I'm proud of what we've built and excited for what's ahead,' said John Czupak, CEO of ThreatQuotient. BTIG, LLC served as exclusive financial advisor, and King & Spalding LLP served as legal advisor to ThreatQuotient. Vinson & Elkins LLP served as legal advisor to Securonix. About Securonix Securonix is leading the transformation of cybersecurity with the industry's first Unified Defense SIEM powered by agentic AI, purpose-built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Built for scale, precision, and speed, our cloud-native platform empowers global enterprises to shift from reactive security to proactive, autonomous operations. Recognized as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers' Choice by Gartner Peer Insights™, Securonix is driving the next era of intelligent, autonomous security operations. Learn more at About ThreatQuotient ThreatQuotient improves security operations by fusing disparate data sources, tools, and teams to accelerate threat detection, investigation, and response (TDIR). ThreatQ is the first purpose-built, data-driven threat intelligence platform that helps teams prioritize, automate, and collaborate on security incidents; enables more focused decision-making; and maximizes limited resources by integrating existing processes and technologies into a unified workspace. The result is reduced noise, clear priority threats, and the ability to automate processes with high-fidelity data. ThreatQuotient's leading integration marketplace, data management, orchestration, and automation capabilities support multiple use cases including threat intelligence management and sharing, incident response, threat hunting, spear phishing, alert triage, and vulnerability management. For more information, visit
